Looking at the filing, I need to find the income tax line and other figures. The filing appears to be cut off. Let me work with what's available.

AdaptHealth Corp. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the SEC on November 3, 2026, reporting a goodwill impairment charge and an operating loss for both the three- and nine-month periods.

Key Highlights

  • Net revenue (Q3 2026): $745,648 thousand for the three months ended September 30, 2026, compared to $672,367 thousand in Q3 2025, according to the filing.
  • Goodwill impairment: The company recorded $184,751 thousand in goodwill impairment for Q3 2026 and $328,987 thousand for the nine months ended September 30, 2026, per the filing.
  • Operating loss: The filing reported an operating loss of $155,919 thousand for Q3 2026, compared to operating income of $43,373 thousand in Q3 2025.
  • Nine-month operating loss: Operating loss of $299,142 thousand for the nine months ended September 30, 2026, versus operating income of $122,478 thousand for the same period in 2025.
  • Accumulated deficit: The company disclosed an accumulated deficit of $936,928 thousand as of September 30, 2026, versus $632,972 thousand as of December 31, 2025.
  • Shares outstanding: As of October 30, 2026, there were 136,525,348 shares of common stock issued and outstanding, the filing stated.
  • Diabetes Health divestiture: The filing cited the company's ability to complete the divestiture of its Diabetes Health business as a forward-looking risk factor, and current assets held for sale from discontinued operations were reported at $177,131 thousand.

AdaptHealth Reports Q3 2026 Operating Loss Amid Goodwill Charges and Revenue Growth

AdaptHealth Corp. (NASDAQ:AHCO), a Delaware-incorporated home health care equipment and services company headquartered in Conshohocken, Pennsylvania, disclosed its unaudited interim consolidated financial results for the three and nine months ended September 30, 2026. The filing reported net revenue of $745,648 thousand for Q3 2026, up from $672,367 thousand in Q3 2025. For the nine-month period, net revenue reached $2,165,828 thousand, compared to $1,974,014 thousand in the prior-year period.

Despite the revenue increase, the company reported a significant operating loss in both the quarter and the year-to-date period, driven primarily by goodwill impairment charges. According to the filing, goodwill impairment totaled $184,751 thousand in Q3 2026 and $328,987 thousand through September 30, 2026, with no comparable impairment recorded in 2025. Total costs and expenses for Q3 2026 were $913,569 thousand, against $628,994 thousand in Q3 2025. The company also recorded a gain on deconsolidation of a subsidiary of $12,002 thousand in Q3 2026 and a gain on sale of businesses of $6,269 thousand for the nine-month period, per the filing.

On the balance sheet, total assets were reported at $4,200,709 thousand as of September 30, 2026, compared to $4,316,577 thousand as of December 31, 2025. Goodwill decreased to $2,158,313 thousand from $2,457,627 thousand over the same period. Total stockholders' equity attributable to AdaptHealth Corp. declined to $1,225,694 thousand from $1,518,562 thousand, reflecting the widening accumulated deficit. Long-term debt, less current portion, rose to $1,867,607 thousand from $1,715,983 thousand. The filing also noted current assets held for sale related to discontinued operations of $177,131 thousand, associated with the company's Diabetes Health business divestiture process. The company disclosed a loss on extinguishment of debt of $1,322 thousand for the nine-month period ended September 30, 2026.

What Was Disclosed

AdaptHealth Corp. disclosed its unaudited Q3 2026 and nine-month financial results, including goodwill impairment of $328,987 thousand year-to-date, an operating loss of $299,142 thousand through September 30, 2026, net revenue growth, and balance sheet changes including an increased accumulated deficit and assets held for sale from discontinued operations.